Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NXGL NASDAQ:NXL OTCMKTS:SIGY OTCMKTS:VASO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNXGLNexGel$2.52-1.2%$2.41$2.10▼$5.10$19.52M0.5970,286 shs3,790 shsNXLNexalin Technology$1.23-3.1%$1.13$0.59▼$4.49$21.82M3.7571,821 shs91,985 shsSIGYSigyn Therapeutics$2.80$2.86$2.49▼$5.75$4.50M-1.1511 shsN/AVASOVaso$0.13-2.3%$0.13$0.11▼$0.32$22.62M1.5336,295 shs19,000 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNXGLNexGel+6.69%+1.59%+8.05%-5.56%+4.08%NXLNexalin Technology+5.83%+24.51%+22.12%-27.43%-5.22%SIGYSigyn Therapeutics0.00%0.00%+1.82%-32.53%-46.67%VASOVaso0.00%+0.78%+1.42%+2.47%-43.53%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNXGLNexGel0.7977 of 5 stars0.03.00.00.02.12.50.0NXLNexalin Technology2.2657 of 5 stars3.55.00.00.00.01.70.0SIGYSigyn TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AVASOVasoN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNXGLNexGel 0.00N/AN/AN/ANXLNexalin Technology 3.00Buy$5.00306.50% UpsideSIGYSigyn Therapeutics 0.00N/AN/AN/AVASOVaso 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNXGLNexGel$8.69M2.22N/AN/A$0.90 per share2.80NXLNexalin Technology$170K124.30N/AN/A$0.28 per share4.39SIGYSigyn TherapeuticsN/AN/AN/AN/A($2.78) per shareN/AVASOVaso$86.77M0.25$0.01 per share12.73$0.16 per share0.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNXGLNexGel-$3.28M-$0.45N/A∞N/A-30.80%-54.95%-27.84%8/18/2025 (Estimated)NXLNexalin Technology-$7.61M-$0.83N/A∞N/A-6,529.77%-277.92%-245.37%8/14/2025 (Estimated)SIGYSigyn Therapeutics-$3.34M-$4.57N/A∞N/AN/AN/A-2,014.27%N/AVASOVaso$950KN/A0.00∞N/A1.20%3.93%1.37%8/12/2025 (Estimated)Latest SIGY, VASO, NXL, and NXGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025SIGYSigyn TherapeuticsN/A-$0.42N/A-$0.42N/AN/A5/15/2025Q1 2025VASOVasoN/A-$0.01N/A-$0.01N/A$19.46 million5/13/2025Q1 2025NXGLNexGel-$0.10-$0.09+$0.01-$0.09$2.73 million$2.81 million5/13/2025Q1 2025NXLNexalin Technology-$0.10-$0.15-$0.05-$0.15$0.04 million$0.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNXGLNexGelN/AN/AN/AN/AN/ANXLNexalin TechnologyN/AN/AN/AN/AN/ASIGYSigyn TherapeuticsN/AN/AN/AN/AN/AVASOVasoN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNXGLNexGel0.151.881.15NXLNexalin TechnologyN/A4.564.25SIGYSigyn TherapeuticsN/A0.010.01VASOVasoN/A1.521.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNXGLNexGel2.21%NXLNexalin Technology0.65%SIGYSigyn Therapeutics10.01%VASOVasoN/AInsider OwnershipCompanyInsider OwnershipNXGLNexGel20.55%NXLNexalin Technology25.26%SIGYSigyn Therapeutics78.46%VASOVaso44.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNXGLNexGel107.65 million6.08 millionNot OptionableNXLNexalin Technology317.18 million12.84 millionNot OptionableSIGYSigyn Therapeutics51.61 million346,000Not OptionableVASOVaso260175.74 million97.54 millionNot OptionableSIGY, VASO, NXL, and NXGL HeadlinesRecent News About These CompaniesGreece stuns USA to reach women’s water polo World Championship finalJuly 23 at 8:11 AM | neoskosmos.comNLevel of physical activity tied to less pain, blood viscosity in SCD: StudyJune 26, 2025 | sicklecellanemianews.comSCorn in a Cup (Elote en Vaso)June 7, 2025 | msn.comOral inhibitor rilzabrutinib granted FDA orphan drug status for SCDJune 5, 2025 | sicklecellanemianews.comSUS FDA grants orphan drug designation to Sanofi’s rilzabrutinib to treat sickle cell diseaseJune 5, 2025 | pharmabiz.comPSanofi Rilzabrutinib gets USFDA orphan drug designation for sickle cell diseaseJune 4, 2025 | medicaldialogues.inMPress Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell diseaseJune 3, 2025 | taiwannews.com.twTSickle cell disease and knee joint pain: Why steriods aren’t always the best optionMay 30, 2025 | punchng.comPVaso Corporation Registered ShsMay 20, 2025 | markets.businessinsider.comVaso Stock Slips Post Q1 Earnings Despite Record Revenue GrowthMay 20, 2025 | zacks.comVaso Corporation Announces Financial Results for First Quarter of 2025May 15, 2025 | globenewswire.comNew tapas and wine bar to open in Nottingham from the team behind MesaMay 6, 2025 | msn.comHe compared him to Justin Bieber, but he got what he deserved in the ringApril 24, 2025 | msn.comThe Zacks Analyst Blog Highlights Apple, Philip Morris International, Sony and VasoApril 21, 2025 | uk.finance.yahoo.comC-Reactive Protein Increases During Menstrual Cycle in Females With Sickle Cell DiseaseApril 18, 2025 | rheumatologyadvisor.comRTop Analyst Reports for Apple, Philip Morris & SonyApril 17, 2025 | finance.yahoo.comShake up your Monday: VASO hosts an electrifying cocktail showdown with top bartendersApril 17, 2025 | myfox28columbus.comMInflammation during menstrual cycle may trigger VOEs: StudyApril 15, 2025 | sicklecellanemianews.comSDangerous 'crises' in sickle cell disease may be amplified by menstrual cycleApril 14, 2025 | msn.comVASO Stock Rises Post Q4 Revenue Growth and Solid Segment GainsApril 7, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSIGY, VASO, NXL, and NXGL Company DescriptionsNexGel NASDAQ:NXGL$2.52 -0.03 (-1.18%) Closing price 03:52 PM EasternExtended Trading$2.54 +0.02 (+0.79%) As of 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.Nexalin Technology NASDAQ:NXL$1.23 -0.04 (-3.15%) Closing price 03:57 PM EasternExtended Trading$1.24 +0.01 (+0.81%) As of 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.Sigyn Therapeutics OTCMKTS:SIGY$2.80 0.00 (0.00%) As of 07/18/2025Sigyn Therapeutics, Inc., a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.Vaso OTCMKTS:VASO$0.13 0.00 (-2.25%) As of 03:28 PM EasternVaso Corporation, together with its subsidiaries, operates in the healthcare equipment and information technology industries in the United States and internationally. The company operates through three segments: IT, Professional Sales Service, and Equipment. The IT segment primarily focuses on healthcare IT and managed network technology services. This segment offers managed diagnostic imaging applications, managed network infrastructure, managed network transport, and managed network security services. The Professional Sales Service segment principally focuses on the sale of healthcare capital equipment for General Electric Healthcare (GEHC) into the health provider middle market. Its offerings include GEHC diagnostic imaging equipment and ultrasound systems, GEHC service agreements, GEHC training, and GEHC and third-party financial services. The Equipment segment primarily focuses on the design, manufacture, sale, and service of proprietary medical devices and software. This segment offers Biox series Holter monitors and ambulatory blood pressure recorders; ARCS series analysis, reporting, and communication software for ECG and blood pressure signals, including cloud-based software and algorithm subscription services; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsation therapy systems for non-invasive and outpatient treatment of ischemic heart disease. The company was formerly known as Vasomedical, Inc. and changed its name to Vaso Corporation in November 2016. Vaso Corporation was incorporated in 1987 and is headquartered in Plainview, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Former Dividend Aristocrat AT&T a Buy After Q2 Earnings? What's Behind Opendoor Technologies' Rally? Is Meme Mania Back? The Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying The Bottom Is in for Kohl’s, But Let the Share Price Come to You Rocket Lab: A Parabolic Run Meets a Healthy Pullback Intuitive Surgical Crushes Q2 Expectations, So Why No Rally? Why Meta’s AI Titan Clusters Are a Game-Changer for Broadcom Block Levels Up: What S&P 500 Inclusion Means for Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
